BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics is also eligible to receive up to approximately $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products under the collaboration.

The significant clinical and preclinical progress across our ADC collaborations, and enthusiasm for our technology as demonstrated by this latest relationship with Bayer, continue to reinforce Seattle Genetics leadership position in the field, said Natasha Hernday, Vice President, Corporate Development, at Seattle Genetics. Across internal and collaborator programs, there are more than 15 ADCs in clinical development using our technology, and we have the potential to receive more than $3.5 billion in future milestones plus royalties from these strategic alliances.

Bayer is committed to translating the science of cancers into effective therapies that can help people with cancer live longer and improve their quality of life, said Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. Antibody-drug conjugates are promising approaches in oncology which can attack tumor cells in a much more targeted way for cancer patients, such that healthy cells are less severely affected. Antibody-drug conjugates are one of our focus areas in oncology research and we are looking forward to strengthening our portfolio in this area of personalized medicine through the collaboration with Seattle Genetics.

ADCs are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells. With over a decade of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cytotoxic agents and stable linker systems that attach these cytotoxic agents to the antibody. Seattle Genetics linker systems are designed to be stable in the bloodstream and release the potent cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The companys lead program, ADCETRIS (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional approval from the European Commission in October 2012. Seattle Genetics also has four other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Celldex, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at http://www.seattlegenetics.com.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the worlds leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCares aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at http://www.healthcare.bayer.com.

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential and future clinical progress, regulatory approval and commercial launch of products utilizing Seattle Genetics ADC technology. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates or our collaborators product candidates move into and advance in clinical trials, risks inherent in early-stage development and failure by Seattle Genetics to secure or maintain relationships with collaborators. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Companys quarterly report on Form 10-Q for the quarter ended March 31, 2013, filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

See the original post here:
Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer

Recommendation and review posted by Bethany Smith

Manila, Philippines --- Several congressmen have indeed undergone stem cell therapy in Germany and two of them died while serving the 15th Congress.

This was gathered from several sources as one outgoing congressman disclosed that a group of Mindanao mayors are set to depart for Europe to visit stem cell clinics in Germany.

''But virility and aesthetic enhancements are the reasons for the trip,'' said outgoing Agham Party-list Rep. Angelo Palmones in an interview yesterday.

Palmones admitted that one of the veteran solons who died during the 15th Congress was a stem cell therapy patient but whether or not the procedure contributed to his death remains unknown.

''He died of heart attack but the purpose of his stem cell treatment was to improve virility,'' said Palmones, outgoing vice chairman of the House Committee on Science and Technology.

Two others reportedly flew to Europe to seek treatment for cancer but both died.

A former broadcaster, Palmones authored House Resolution No. 1075 calling for a congressional investigation in aid of legislation on the operation of stem cell therapy clinics in malls in a bid to ensure the ''safety and security of patients.''

In a press statement the other day, the Philippine Medical Association (PMA) aired suspicions that ''three politicians'' from Mindanao may have died due to stem cell treatments from unauthorized practitioners.

Read more from the original source:
Was Stem Cell therapy behind death of 3 Solons?

Recommendation and review posted by simmons

Usapang Pangkalusugan - Stem Cell Therapy

By: untvweb

Read more:
Usapang Pangkalusugan - Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Sophie
This is a before video of Sophie. You can see she is trembling due to t he pain in her hips.

By: Tim O #39;Neill, DVM

Read the original here:
Stem Cell Therapy Sophie - Video

Recommendation and review posted by Bethany Smith

Sugar 6 months post femeral head osteotomy with stem cell therapy
Sugar had her femeral head and neck of the bone surgically removed and stem cells put into the hip socket 6 months before this was taken. It was amazing to s...

By: Tim O #39;Neill, DVM

Continue reading here:
Sugar 6 months post femeral head osteotomy with stem cell therapy - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Treatment for Right brachial Plexopathy by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Right brachial Plexopathy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. T...

By: neurogenbsi

Continue reading here:
Stem Cell Therapy Treatment for Right brachial Plexopathy by Dr Alok Sharma, Mumbai, India. - Video

Recommendation and review posted by Bethany Smith

MANILA - House Speaker Sonny Belmonte said 2 congressmen died after having stem cell therapy overseas.

These are congressmen Erico Aumentado and Pedro Romualdo.

Belmonte, however, clarified that it has not been established whether stem cell therapy was the cause of death.

Belmonte said that after having stem cell therapy, the 2 felt rejuvenated and may have exerted themselves during the last election campaign.

Belmonte said Aumentado even started walking around without a cane.

Aumentado' son Aristotle, a first-term congressman, was introduced by Belmonte to media during the sidelines of the executive course the lower House sponsored for neophytes.

Aristotle said his father died of pneumonia. He added there is also no proof that stem cell caused the death.

In fact, he said they were scheduled for another treatment after the elections had his father not died.

Aristotle said the Philippine Medical Association (PMA) has not approached them for the PMA's investigation into the deaths of 3 politicians who died after receiving stem cell therapy abroad.

Aristotle explained that his father had leg thrombosis for which he had to undergo bifemoral bypass and stem cell therapy .

Read more:
2 congressmen who died after stem cell therapy named

Recommendation and review posted by Bethany Smith

Manila (Philippine Daily Inquirer/ANN) - This stem cell therapy could be hazardous to your health.

The Philippine Medical Association (PMA) on Sunday warned Filipinos against availing themselves of the so-called "xenogenic" stem cell therapy from foreign doctors who fly into the country and perform the procedure in five-star hotels in Metro Manila.

The doctors' organisation also announced that it had already tapped the help of the National Bureau of Investigation and the Philippine National Police to look into the scam, which it said tainted the legitimate practice of stem cell or regenerative medicine in the country.

Dr. Leo Olarte, PMA president and spokesperson of the Philippine Society for Stem Cell Medicine (PSSCM), disclosed that the two medical groups had received complaints from patients and their relatives who had undergone such stem cell procedures allegedly performed in the country by German doctors.

Based on the complaints, Olarte said the patients were asked to check in at a five-star hotel in the capital, where they were injected with animal-based stem cells at around 1 million pesos (US$22,800) per shot.

"These foreigners are not even licensed to practice medicine in the country and are in violation of the Medical Act of 1959," Olarte stressed. "We are then asking government regulators and enforcers, especially the NBI and the PNP, to investigate these criminal acts."

He warned Filipino doctors to stop collaborating with unscrupulous foreign counterparts or the organisation would file criminal cases against them.

"If you will continue doing this, we will file criminal cases against you," said Olarte, an orthopedic surgeon and practising lawyer.

The doctor also stressed that the autologous adult stem cell treatmentderived from the patient's own blood, bone marrow or fatwas the only approved stem cell therapy by the Department of Health (DOH) because it had already been proven as the safest procedure available worldwide.

He discouraged Filipinos from considering xenogenic stem cell sources or those derived from animals and plants, as well as allogeneic sources or from other human beings, due to the many instances of deadly complications from these procedures.

Read more here:
Stem cell therapy in Philippines' 5-star hotels a scam, says group

Recommendation and review posted by Bethany Smith

Public release date: 24-Jun-2013 [ | E-mail | Share ]

Contact: Jeffrey Norris jeff.norris@ucsf.edu 415-502-6397 University of California - San Francisco

Gene mutations that cause cell signaling networks to go awry during embryonic development and lead to major birth defects may also cause subtle disruptions in the brain that contribute to psychiatric disorders such as schizophrenia, autism, and bipolar disorder, according to new research by UC San Francisco scientists.

Over the past several years, researchers in the laboratory of psychiatrist Benjamin Cheyette, MD, PhD, have shown that mice with mutations in a gene called Dact1 are born with a range of severe malformations, including some reminiscent of spina bifida in humans.

In a new study designed to explore whether Dact1 mutations exert more nuanced effects in the brain that may lead to mental illness, Cheyette, John Rubenstein, MD, PhD, and colleagues in UCSF's Nina Ireland Laboratory of Developmental Neurobiology used a genetic technique in mice to selectively delete the Dact1 protein only in interneurons, a group of brain cells that regulates activity in the cerebral cortex, including cognitive and sensory processes. Poor function of interneurons has been implicated in a range of psychiatric conditions.

As reported in the June 24, 2013 online issue of PLOS ONE, when the research team examined these genetically altered interneurons in adult mice, they found that the cells appeared relatively normal and had managed to find their proper position in the brain's circuitry during development. But the cells had significantly fewer synapses, the sites where communication with neighboring neurons takes place. In additional observations not included in the new paper, the team also noted that the cells' dendrites, fine extensions that normally form bushy arbors studded with synapses, were poorly developed and sparsely branched.

"When you delete this gene function after initial, early development -- just eliminating it in neurons after they've formed -- they migrate to the right place and their numbers are correct, but their morphology is a little off," Cheyette said. "And that's very much in line with the kinds of pathology that people have been able to identify in psychiatric illness. Neurological illnesses tend to be focal, with lesions that you can identify or pathology you can see on an imaging study. Psychiatric illnesses? Not so much. The differences are really subtle and hard to see."

The Dact1 protein is part of a fundamental biological system known as the Wnt (pronounced "wint") signaling pathway. Interactions among proteins in the Wnt pathway orchestrate many processes essential to life in animals as diverse as fruit flies, mice, and humans, including the proper development of the immensely complex human nervous system from a single fertilized egg cell.

One way the Wnt pathway manages this task is by maintaining the "polarity" of cells during development, said Cheyette, "a process of sequestering, increasing the concentration of one set of proteins on one side of the cell and a different set of proteins on the other side of the cell." Polarity is particularly important as precursor cells transform into nerve cells, Cheyette said, because neurons are "the most polarized cells in the body," with specialized input and output zones that must wind up in the proper spots if the cells are to function normally.

Cheyette said his group is now conducting behavioral experiments with the mice analyzed in the new PLOS ONE paper and with genetically related mouse lines to test whether these mice have behavioral abnormalities in sociability, sensory perception, anxiety, or motivation that resemble symptoms in major psychiatric disorders. He also hopes to collaborate with UCSF colleagues on follow-up experiments to determine whether the activity of neurons lacking Dact1 is impaired in addition to the structural flaws identified in the new study and prior published work from his lab.

Read this article:
Genes involved in birth defects may also lead to mental illness

Recommendation and review posted by Bethany Smith

By: Jet Villa, InterAksyon.com June 25, 2013 10:48 AM

Last week, the Court of Appeals stopped the genetic engineering of Bacillus thuringiensis (Bt) eggplants nationwide. FILE PHOTO

InterAksyon.com The online news portal of TV5

MANILA, Philippines - A week after the Court of Appeals stopped the genetic engineering of Bacillus thuringiensis (Bt) eggplants nationwide, the Food and Drug Administration (FDA) on Tuesday said genetically-modified (GM) foods produced through modern biotechnology are safe.

In FDA Advisory No. 2013-014, the FDA said that all food derived from GM crops in the market have met international food standards and are as safe as and as nutritious as the food derived from conventional crops for direct use as food, feeds, and for processing.

"The FDA hereby reiterates that all GM food products derived from modern biotechnology that are currently on the market have passed food safety assessment based on the UN FAO/WHO CODEX Alimentarius Risk Analysis of Food Derived from Modern Biotechnology and Guidelines for the Conduct of Food Safety Assessment of Foods Derived from Recombinant-DNA Plants," FDA Advisory No. 2013-014 said.

The FDA said the safety of these specific GM crops should be assessed on a case-by-case basis, following the CODEX Alimentarius guidelines for determining their safety, including toxicity, allergenicity, and nutritional quality, or assessment of any nutritional claim.

"It is not possible to make general statements on the safety of all GM foods. As the national competent authority, the FDA supports the robust science-based evaluation system of CODEX Alimentarius Commission using data and information from field trials as well as laboratory tests," the FDA said.

"For processed food, the main focus of food safety review is on the objective characteristics of the product and on any health or nutritional claims. The focus of evaluation is on the food product and not on the technology used to produce the product," it said.

GM penetration rate

View original post here:
Genetically-modified foods produced through modern biotechnology are safe - FDA

Recommendation and review posted by Bethany Smith

24 June 2013

GE controls need strengthening, not slashing

The Green Party is calling for Environment Minister Amy Adams to back off from her threats to strip councils of their power to regulate for genetic engineering in their communities.

The New Zealand Herald today reported that the Minister is investigating how to change the law to stop councils from putting in place controls on genetic engineering (GE) in their communities.

These councils have established that our current regulations dont adequately cover them or farmers in the event of a GE contamination and they need to step in and provide those protections, said Green Party GE spokesperson Steffan Browning.

So what is this Governments response? Same as usual, change the law to take away local democracy.

The controls that councils are putting in pace would place the responsibility, accountability, and liability on the person or company growing the crops, which is where it should be.

This is how nuclear-free New Zealand started, with local councils taking the stand their community wanted them to take and that is a stance that the whole country is very proud of now.

This Government wants to strip local councils of their ability to regulate what happens in their own regions.

Without adequate regulation from central government the burden of risk for GE is placed entirely in the wrong place; on GE-free farmers whose crops have been contaminated from neighbouring GE farms, and on the councils themselves.

View original post here:
GE controls need strengthening, not slashing

Recommendation and review posted by Bethany Smith

The Green Party is calling for Environment Minister Amy Adams to back off from her threats to strip councils of their power to regulate for genetic engineering in their communities.

The New Zealand Herald today reported that the Minister is investigating how to change the law to stop councils from putting in place controls on genetic engineering (GE) in their communities.

"These councils have established that our current regulations dont adequately cover them or farmers in the event of a GE contamination and they need to step in and provide those protections," said Green Party GE spokesperson Steffan Browning.

"So what is this Governments response? Same as usual, change the law to take away local democracy.

"The controls that councils are putting in pace would place the responsibility, accountability, and liability on the person or company growing the crops, which is where it should be.

"This is how nuclear-free New Zealand started, with local councils taking the stand their community wanted them to take and that is a stance that the whole country is very proud of now.

"This Government wants to strip local councils of their ability to regulate what happens in their own regions.

"Without adequate regulation from central government the burden of risk for GE is placed entirely in the wrong place; on GE-free farmers whose crops have been contaminated from neighbouring GE farms, and on the councils themselves.

"Its entirely rational for a council to ask GE growers to put aside resources to pay for any crop contamination, and to publically notify an application to release GE crops. Farmers have a right to know if their neighbours are going to be using GE, and ratepayers shouldnt have to pay for contamination or liability costs.

"Councils are working hard to meet the needs of their local communities; they dont need Minister Adams rolling in and riding roughshod over their local democracy," Mr Browning said.

Read more:
GE controls need strengthening, not slashing - Adams

Recommendation and review posted by Bethany Smith

REDWOOD SHORES, CA--(Marketwired - Jun 24, 2013) - Oracle (NASDAQ: ORCL)

News Facts

Supporting Quotes

Supporting Resources

About Oracle Oracle engineers hardware and software to work together in the cloud and in your data center.For more information about Oracle (NASDAQ: ORCL), visit http://www.oracle.com.

About Oracle in IndustriesOracle industry solutions leverage the company's best-in-class portfolio of products to address complex business processes relevant to health sciences, helping speed time to market, reduce costs, and gain a competitive edge.

About Oracle Health SciencesAt Oracle, we believe that a more predictive, preventive, personalized and participatory system will help improve human health.We can help accelerate this journey to personalized medicine through technology, data and insights. Oracle's solutions support industry initiatives to improve care quality and outcomes, reduce costs, and speed time to market for new treatments, therapies and devices.For more information, visit http://www.oracle.com/us/industries/health-sciences/index.html

TrademarksOracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Read the original here:
Genetic Alliance Selects Oracle Health Sciences Network to Help Patients Gain Access to Clinical Trials

Recommendation and review posted by Bethany Smith

25 Years ALH-Genetics Movie "Adolf #39;s-Genetics"
Impression of the development of ALH-Genetics and it #39;s owner Adolf Langhout.

By: ALHLongwood

More here:
25 Years ALH-Genetics Movie "Adolf's-Genetics" - Video

Recommendation and review posted by Bethany Smith

Feeding the World through Plant Breeding and Genetics
Ariel Chan, a graduate student at Cornell University, discusses how advances in plant breeding and genetics are essential to secure the world #39;s food supply i...

By: plantbreedgenomics

See original here:
Feeding the World through Plant Breeding and Genetics - Video

Recommendation and review posted by Bethany Smith

Australian fetuses could become alcoholics and drug addicts before they even leave the womb, new research shows.

The National Drug and Alcohol Research Centre (NDARC) at the University of NSW reveals that genetics and family history can increase the risk of young Australians developing addictions.

NDARC director Professor Michael Farrell at a speech to be delivered on Tuesday night will say that the research helps to determine which genetic and social factors lead to drug and alcohol abuse, as well as mental health problems later in life.

'While we need to recognise there are varying degrees of mental ill health and that it's a complex issue, research confirms that early detection of certain contributing factors is possible,' Dr Farrell said in a statement.

'With the growing trend for buying drugs online and using synthetic drugs or legal highs' among young Australians, now is the time to focus on these solutions.'

The UNSW Medicine Dean's Lecture will address a range of issues affecting young people, including the self-harm epidemic, the effects of adolescent exposure to drugs and alcohol on the wider community and how early intervention might save them, as well as offering preventative solutions for mental illness and risky behaviours.

One in two young Australians suffer from mental illness, said Pat McGorry, Professor of Youth Mental Health at the University of Melbourne.

He said studies indicated that mental illness experienced in their childhood can impact people's jobs and social lives well into their 30s, including having a lower earning capacity and fewer friends.

Mental health costs the Australian economy $7 billion a year, a figure that is set to double over the next 20 years.

The issue doesn't discriminate and can affect any household, said Professor McGorry.

Go here to see the original:
Genetics key to addicted children

Recommendation and review posted by Bethany Smith

A bearish trade dominates today's option activity in Seattle Genetics. Total option volume in SGEN is 9,085 contracts so far, compared to a daily average of just 572 in the last month. Virtually all of the volume is in one three-way put combination.

optionMONSTER systems show that a trader bought 3,000 September 25 puts for the ask price of $1.60 and, seconds later, sold 3,000 September 20 puts for $0.45 to create a vertical spread . He or she then sold 1,800 September 35 calls for $1.20 and another 1,200 for $1.25. The volume at all three strikes was multiples of the open interest, so this is a new position.

The bearish strategy will take a maximum profit if SGEN is at or below $25 at expiration, while the trader risks having to sell shares above $35. This could also be a collar to protect long shares, at least down to that lower strike. (See our Education section)

SGEN is down 2.24 percent to $29.62 this morning, its lowest level since early March. Shares of the biopharmaceutical company were up to $39 toward the end of April but have been trending lower since retesting that level in mid-May.

More From optionMONSTER

Read this article:
Bearish 3-way bet in Seattle Genetics

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Good Start Genetics, Inc.,an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its GoodStart Select carrier screening tests to in-vitro fertilization (IVF) and other reproductive health practitioners in the state. GoodStart Select, the companys menu of carrier screening tests, detects far more disease-causing mutations than any other carrier screening test routinely used in clinical practice. With this license, Good Start becomes the first laboratory to offer extensively validated NGS-based carrier screening in New York, where nearly 25 percent of all reproductive health carrier screening is performed each year.

Couples planning to conceive want to make sure they have the healthiest pregnancy possible, said David L. Keefe, M.D., Stanley H. Kaplan Professor of Obstetrics and Gynecology and chair, Department of Obstetrics and Gynecology at NYU Langone Medical Center. Good Start's approach to pre-conceptual genetic testing draws on the latest technology developed from the Human Genome Project and delivers remarkable accuracy and sensitivity in the detection of genetic conditions that might afflict their baby.

We congratulate Good Start on being awarded its New York state license and look forward to offering the next generation of genetic testing to our patients, adds Alan Copperman M.D., co-director of Reproductive Medicine Associates of New York, vice chairman of the Department of Obstetrics, Gynecology, and Reproductive Science at Mount Sinai Medical Center, and long-standing adviser to Good Start Genetics.

GoodStart Select was launched in the U.S. in April 2012. Since then, Good Start Genetics high-complexity, CLIA- and CAP-accredited laboratory has processed well over 100,000 tests, detecting both common disease-causing mutations as well as rare, pathogenic mutations that would have otherwise gone undetected by laboratories using traditional genotyping-based technologies. Last week, Good Start Genetics published its comprehensive validation study in Genomics in Medicine.

In addition, Good Starts tests are clinically validated to detect genetic mutations specific to individuals of Ashkenazi Jewish or Eastern European descent. Nearly one in three Ashkenazi Jews in the U.S. is a carrier of at least one of 19 severe inherited diseases, and one-third of the U.S. Jewish population, the vast majority of which are Ashkenazi, resides in the state of New York.

Obtaining the New York state license is an important achievement for Good Start, and were very proud our operation has passed the rigorous New York inspection and approval process, said Don Hardison, president and chief executive officer of Good Start Genetics. We have seen strong adoption by reproductive health specialists across the country, and now look forward to providing our highly accurate and clinically actionable tests to physicians and patients in New York.

About GoodStart Select

GoodStart Select is Good Start Genetics menu of carrier screening tests that, for diseases such as cystic fibrosis, detects many more disease-causing mutations than any other routine carrier screening test, regardless of patient ethnicity. After years of development and rigorous validation, Good Start Genetics has harnessed the power of its sophisticated technologies, including next-generation DNA sequencing (NGS), to provide highly accurate and actionable tests resulting in higher mutation detection rates and fewer missed carriers. Good Start offers genetic screening tests for all disorders recommended by the American Congress of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG), and leading Jewish advocacy groups.

To support the companys gold standard genetic screening capabilities, Good Start has a dedicated team of customer care specialists, board certified medical geneticists and genetic counselors who provide step-by-step support, from test selection through results, analysis and reporting. For these reasons, reproductive health specialists and their patients can have the highest degree of confidence in their genetic carrier screening results.

Here is the original post:
Good Start Genetics Receives Approval to Conduct Genetic Screening in New York

Recommendation and review posted by Bethany Smith

Gene Therapy for the Treatment of Hemophilia B: Andrew M. Davidoff, MD at TEDxSonomaCounty
Andrew Davidoff, MD is the Chairman of the Department of Surgery at St. Jude Children #39;s Research Hospital and the St. Jude Children #39;s Research Hospital Endow...

By: TEDxTalks

See the article here:
Gene Therapy for the Treatment of Hemophilia B: Andrew M. Davidoff, MD at TEDxSonomaCounty - Video

Recommendation and review posted by Bethany Smith

Gene Therapy for Parkinson #39;s Disease
An animation shows what happens during gene therapy for Parkinson #39;s Disease.

By: BrainSpineCenter

More here:
Gene Therapy for Parkinson's Disease - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Clinics - Regenerative Medicine with Research Studies
http://r3stemcell.com R3 Stem Cell Clinics offer stem cell injection treatments, such as platelet rich plasma therapy, bone marrow derived stem cells and amn...

By: USPainNetwork

See the original post here:
Stem Cell Therapy Clinics - Regenerative Medicine with Research Studies - Video

Recommendation and review posted by simmons

Rylee May Post Stem Cell Therapy
This was taken about 7-8 months after stem cell therapy. We have a great improvement in the ability to walk without pain from hip dysplasia.

By: Tim O #39;Neill, DVM

See original here:
Rylee May Post Stem Cell Therapy - Video

Recommendation and review posted by simmons

By: Jet Villa, InterAksyon.com June 24, 2013 12:16 PM

REUTERS FILE PHOTO

InterAksyon.com The online news portal of TV5

MANILA, Philippines - The Philippine Medical Association (PMA) is verifying media reports that at least three politicians from Mindanao died after undergoing stem cell treatment in Germany.

Citing media reports, PMA president Dr. Leo Olarte said the three politicians went through the procedures as they were trying to seek cure for pneumonia, liver cancer, and heart disease.

Hindi pa natin masasabi kung namatay sila because of stem cell therapy or because of other illnesses.Kailangan pa nating mag-imbestiga, said Olarte, who is also the spokesman of the Philippine Society for Stem Cell Medicine.

He said the three could have been given stem cells from sheep and rabbits since these are allowed as sources of stem cells in Germany.

We were told that the two died one year after (their respective) procedures.One of them died in April, yung isa noong (the other one in) May, he said.

Olarte admitted PMA still does not have the identities of the politicians but the PMA will send a team to Mindanao to coordinate with their members there to trace their families.

He said while the PMA has no jurisdiction over the doctors who performed the procedure, establishing the connection of the therapy to the politicians death could serve as a warning to those who received xenogenic stem cells or those derived from animals.

Read the rest here:
PMA verifying reports that stem-cell therapy in Germany killed 3 Mindanao politicians

Recommendation and review posted by simmons

By Jocelyn R. Uy Philippine Daily Inquirer

This stem cell therapy could be hazardous to your health.

The Philippine Medical Association (PMA) on Sunday warned Filipinos against availing themselves of the so-called xenogenic stem cell therapy from foreign doctors who fly into the country and perform the procedure in five-star hotels in Metro Manila.

The doctors organization also announced that it had already tapped the help of the National Bureau of Investigation and the Philippine National Police to look into the scam, which it said tainted the legitimate practice of stem cell or regenerative medicine in the country.

Dr. Leo Olarte, PMA president and spokesperson of the Philippine Society for Stem Cell Medicine (PSSCM), disclosed that the two medical groups had received complaints from patients and their relatives who had undergone such stem cell procedures allegedly performed in the country by German doctors.

Based on the complaints, Olarte said the patients were asked to check in at a five-star hotel in the capital, where they were injected with animal-based stem cells at around P1 million per shot.

These foreigners are not even licensed to practice medicine in the country and are in violation of the Medical Act of 1959, Olarte stressed. We are then asking government regulators and enforcers, especially the NBI and the PNP, to investigate these criminal acts.

He warned Filipino doctors to stop collaborating with unscrupulous foreign counterparts or the organization would file criminal cases against them.

If you will continue doing this, we will file criminal cases against you, said Olarte, an orthopedic surgeon and practicing lawyer.

The doctor also stressed that the autologous adult stem cell treatmentderived from the patients own blood, bone marrow or fatwas the only approved stem cell therapy by the Department of Health (DOH) because it had already been proven as the safest procedure available worldwide.

Continue reading here:
Stem cell therapy in 5-star hotels? Group sees scam

Recommendation and review posted by simmons

Spinal cord injury wheelchair racing on the street top sped 31,6 km 21 6 2013
Arnar Helgi Lrusson sci 2002 T2/3 complete This video is since 2013 visit my website http://www.wix.com/amcorp/sci.

By: Arnar lrusson

See more here:
Spinal cord injury wheelchair racing on the street top sped 31,6 km 21 6 2013 - Video

Recommendation and review posted by sam